Latest:
Direct Targeting of RET Aberrations Moves Closer to the Clinic
Over the past 30 years, from the discovery of a fusion rearrangement to the recent promise of LOXO-292, RET targeting has gone from distant concept toward clinical reality.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
William R. Jarnagin, MD
Latest:
Dr. Jarnagin on Surgical Protocols for CRC That Have Spread Beyond the Liver
William R. Jarnagin, MD, FACS, chief, Hepatopancreatobiliary Service, Benno C. Schmidt Chair, Surgical Oncology, Memorial Sloan Kettering Cancer Center, discusses the surgical barriers in treating patients with colorectal cancer that has metastasized outside of the liver.
William R. Jarnagin, MD, FACS
Latest:
Dr. Jarnagin on the Improvements in Surgery for Patients With mCRC
William R. Jarnagin, MD, FACS, chief, Hepatopancreatobiliary Service, Benno C. Schmidt Chair, Surgical Oncology, Memorial Sloan Kettering Cancer Center, discusses the progression of surgery in treating patients with metastatic colorectal cancer.
William T. Lowrance, MD
Latest:
The Effect of Prostate MRI on Cancer Staging and Radiotherapy Treatment Recommendations
Researchers evaluate the role of magnetic-resonance imaging in the clinical staging of prostate
cancer in the definitive and salvage settings, and to identify changes in treatment recommendations.
Winald Gerritsen, MD, PhD
Latest:
Dr. Gerritsen on a Study of Alisertib in Neuroendocrine Prostate Cancer
Winald Gerritsen, MD, PhD, professor and medical oncologist, Radboud Medical Center, discusses a phase II study that examined the activity of alisertib monotherapy in patients with neuroendocrine prostate cancer.
Wojciech Jurczak, MD
Latest:
Dr. Wojciech Jurczak on MOR208 in Non-Hodgkin's Lymphoma
Wojciech Jurczak, MD Head of Lymphoma, Department of Hematology, Jagiellonian University, Kopernika, Poland, discuses a subgroup analyses of diffuse large b-cell lymphoma (DLBCL) and indolent lymphoma cohorts from a phase IIa study of single-agent MOR208 in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL).